Literature DB >> 15155227

Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus.

Anna L Salvati1, Alessandra De Dominicis, Sabrina Tait, Andrea Canitano, Armin Lahm, Lucia Fiore.   

Abstract

The mechanism of action of the antiviral compound 3(2H)-isoflavene against Sabin type 2 poliovirus has been studied, and interference with virus uncoating was demonstrated. Isolation and sequencing of drug-resistant variants revealed single amino acid substitutions (I194M or D131V) in the VP1 capsid protein. While M194 is located in a hydrophobic pocket and should partially fill the space occupied by the isoflavene ring, V131 is exposed on the VP1 surface, forming a contact with VP4. The D131V mutation most likely induces local conformational changes in VP1 and/or VP4 that affect viral flexibility. Two dependent variants, N53S of VP1 and K58E of VP4, both located on the inner surface of the capsid, near the threefold axis of symmetry, were also selected. Both mutations affected viral stability, allowing the transition to 135S particles in the absence of drug, without the involvement of the viral receptor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155227      PMCID: PMC415587          DOI: 10.1128/AAC.48.6.2233-2243.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  51 in total

Review 1.  Antiviral therapy for enteroviral infections.

Authors:  H A Rotbart
Journal:  Pediatr Infect Dis J       Date:  1999-07       Impact factor: 2.129

2.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

3.  Poliovirus 2C region functions during encapsidation of viral RNA.

Authors:  L M Vance; N Moscufo; M Chow; B A Heinz
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine.

Authors:  S R Pollard; G Dunn; N Cammack; P D Minor; J W Almond
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

5.  Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants.

Authors:  H Toyoda; M Kohara; Y Kataoka; T Suganuma; T Omata; N Imura; A Nomoto
Journal:  J Mol Biol       Date:  1984-04-25       Impact factor: 5.469

6.  Effect of arildone on modifications of poliovirus in vitro.

Authors:  L A Caliguiri; J J McSharry; G W Lawrence
Journal:  Virology       Date:  1980-08       Impact factor: 3.616

7.  Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors.

Authors:  D C Pevear; M J Fancher; P J Felock; M G Rossmann; M S Miller; G Diana; A M Treasurywala; M A McKinlay; F J Dutko
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

8.  Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design.

Authors:  R A Grant; C N Hiremath; D J Filman; R Syed; K Andries; J M Hogle
Journal:  Curr Biol       Date:  1994-09-01       Impact factor: 10.834

9.  Effect of chloro-, cyano-, and amidino-substituted flavanoids on enterovirus infection in vitro.

Authors:  D Genovese; C Conti; P Tomao; N Desideri; M L Stein; S Catone; L Fiore
Journal:  Antiviral Res       Date:  1995-05       Impact factor: 5.970

10.  Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials.

Authors:  Frederick G Hayden; Darrell T Herrington; Teresa L Coats; Kenneth Kim; Ellen C Cooper; Stephen A Villano; Siyu Liu; Spencer Hudson; Daniel C Pevear; Marc Collett; Mark McKinlay
Journal:  Clin Infect Dis       Date:  2003-06-06       Impact factor: 9.079

View more
  11 in total

1.  Viral adaptation to an antiviral protein enhances the fitness level to above that of the uninhibited wild type.

Authors:  James E Cherwa; Pablo Sanchez-Soria; Holly A Wichman; Bentley A Fane
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

2.  From resistance to stimulation: the evolution of a virus in the presence of a dominant lethal inhibitory scaffolding protein.

Authors:  James E Cherwa; Bentley A Fane
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

3.  Mechanism of action and capsid-stabilizing properties of VHHs with an in vitro antipolioviral activity.

Authors:  Lise Schotte; Mike Strauss; Bert Thys; Hadewych Halewyck; David J Filman; Mihnea Bostina; James M Hogle; Bart Rombaut
Journal:  J Virol       Date:  2014-02-05       Impact factor: 5.103

4.  Modelling and targeting mitochondrial protein tyrosine phosphatase 1: a computational approach.

Authors:  Venkataraghavan Ragunathan; K Chithra; C Shivanika; Meenambiga Setti Sudharsan
Journal:  In Silico Pharmacol       Date:  2022-01-17

5.  Antiviral activity of 3(2H)- and 6-chloro-3(2H)-isoflavenes against highly diverged, neurovirulent vaccine-derived, type2 poliovirus sewage isolates.

Authors:  Lester M Shulman; Danit Sofer; Yossi Manor; Ella Mendelson; Jean Balanant; Anna Laura Salvati; Francis Delpeyroux; Lucia Fiore
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

6.  Anti-Japanese-encephalitis-viral effects of kaempferol and daidzin and their RNA-binding characteristics.

Authors:  Ting Zhang; Zhiqiang Wu; Jiang Du; Yongfeng Hu; Liguo Liu; Fan Yang; Qi Jin
Journal:  PLoS One       Date:  2012-01-20       Impact factor: 3.240

7.  Antiviral Ability of Kalanchoe gracilis Leaf Extract against Enterovirus 71 and Coxsackievirus A16.

Authors:  Ching-Ying Wang; Shun-Chueh Huang; Yongjun Zhang; Zhen-Rung Lai; Szu-Hao Kung; Yuan-Shiun Chang; Cheng-Wen Lin
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-15       Impact factor: 2.629

Review 8.  Soy isoflavones and virus infections.

Authors:  Aline Andres; Sharon M Donovan; Mark S Kuhlenschmidt
Journal:  J Nutr Biochem       Date:  2009-08       Impact factor: 6.048

9.  Potent antiviral agents fail to elicit genetically-stable resistance mutations in either enterovirus 71 or Coxsackievirus A16.

Authors:  James T Kelly; Luigi De Colibus; Lauren Elliott; Elizabeth E Fry; David I Stuart; David J Rowlands; Nicola J Stonehouse
Journal:  Antiviral Res       Date:  2015-10-30       Impact factor: 5.970

10.  Antiviral and Antioxidant Activity of a Hydroalcoholic Extract from Humulus lupulus L.

Authors:  Antonella Di Sotto; Paola Checconi; Ignacio Celestino; Marcello Locatelli; Stefania Carissimi; Marta De Angelis; Valeria Rossi; Dolores Limongi; Chiara Toniolo; Lucia Martinoli; Silvia Di Giacomo; Anna Teresa Palamara; Lucia Nencioni
Journal:  Oxid Med Cell Longev       Date:  2018-07-24       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.